Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Future directions in glioblastoma: the potential role of TKIs

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.05.19
Views: 494
Rating:

Prof Roger Stupp, Dr Giuseppe Lombardi

Current treatment options are very limited for recurrent glioblastoma. Not only are these a complex tumour type, their location adds an additional factor: the blood-brain barrier, which can prevent pharmacotherapies from reaching tumour cells.

The REGOMA trial was a phase 2 trial to investigate the efficacy and safety of regorafenib in treating recurrent glioblastoma after radiotherapy/temozolomide. The highly vascular nature of the tumour renders regorafenib a potentially efficacious agent, and the results of this phase 2 trial indicate a possible use in cases of relapsed glioblastoma.

Chaired by Professor Roger Stupp and featuring guest author Dr Giuseppe Lombardi, this session summarises the key findings of the trial and explores the potential future of regorafenib in the treatment of glioblastoma.

This independent educational activity is supported by an educational grant from Bayer Pharmaceuticals.

The educational content has been developed by Liberum IME and validated by an independent steering committee; Bayer Pharmaceuticals have had no influence on the content of this education.

If you are from Spain or Italy and want to listen to advice from experts from your country please visit Oncology knowledge into practice.

Related videos

follow us

WIN 2019


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation